Avistone's Vebreltinib Revolution: MET Exon 14 Approval Sparks New Era in Lung Cancer Care
Автор: Pharma News & Analysis
Загружено: 2023-11-22
Просмотров: 41
Описание:
🔍 Dive into the groundbreaking news as Avistone Biotechnology secures conditional approval from the NMPA for Vebreltinib, heralding a new era in MET-targeted treatment for MET exon 14 skipping non-small cell lung cancer (NSCLC) patients in China.
🩸 Key Highlights:
🆕 Conditional approval for Vebreltinib's commercialization in China.
📊 Pivotal Phase II KUNPENG study results: 75.0% ORR and 14.1 months PFS.
🌐 Advancements in precision oncology therapeutics.
🔬 Understanding MET Signaling:
🧬 The role of MET signaling in cell processes and its implications.
📈 METex14 as an independent prognostic factor in NSCLC.
🌐 Global Impact:
🌍 Avistone's exclusive rights to Vebreltinib in China, Hong Kong, and Macau.
💉 Transformative potential for METex14 NSCLC patients.
🔔 Stay Informed! Subscribe for more updates on revolutionary oncology treatments! 🔔
🌈 Connect with Us:
Join the Whatsapp Group:
https://chat.whatsapp.com/JmGCjK5vTJr...
Follow us on the Whatsapp Channel
https://whatsapp.com/channel/0029VaBq...
Join the Telegram Group:
https://t.me/pharmanewsandanalysis
🔍 #Vebreltinib #AvistoneBiotech #LungCancerTreatment #METex14 #PrecisionOncology #NMPAApproval #ESMO2023 #MedicalBreakthrough #SubscribeNow
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
